KIA
ARKG icon

Kraematon Investment Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Kraematon Investment Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-856
Closed -$24.2K – 89
2022
Q4 		$24.2K Buy
+856
New +$27.2K 0.03% 159

Other funds holding ARKG

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Kraematon Investment Advisors's ARKG Position: Q1 2023 in Review

Kraematon Investment Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2023, closing a stake of 856 shares — an estimated $24.2K sold.

Kraematon Investment Advisors first reported a position in ARKG in Q4 2022 and held it in 1 quarter. The position peaked at $24.2K in Q4 2022. 297 funds tracked by Wall St. Rank hold ARKG as of Q1 2023.

  • Kraematon Investment Advisors reported no remaining ARK Genomic Revolution ETF position as of Q1 2023 after selling out during the quarter.
  • Kraematon Investment Advisors sold 856 ARK Genomic Revolution ETF shares in Q1 2023, an estimated $24.2K.
  • Kraematon Investment Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2022 and held it in 1 quarter.
  • Kraematon Investment Advisors's ARK Genomic Revolution ETF position peaked at $24.2K in Q4 2022.
  • 297 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2023.

Based on Kraematon Investment Advisors's 13F filing for Q1 2023, filed 13 Apr 2023.